Dr. Christine Desbiens is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Université Laval and clinical professor at the Faculty of Medicine of Laval University. Dr. Desbiens is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.
Dr. Desbiens is the leader of the Canadian Clinical Trial Group at Saint-Sacrement Hospital of the CHU de Québec. She is also the medical director for the Centre des Maladies du Sein du CHU de Québec.
Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and management of cancers and benign breast diseases.
Offer innovative treatments
The research group of the Centre des Maladies du Sein of the CHU de Québec-Laval University is one of the largest research groups in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times, and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.
Support the quality of life
The Centre des Maladies du Sein of the CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life, despite the disease’s life trial.
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Canada G1S 4L8
Data not available
Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical TrialJournal Article
Ann Surg Oncol, 29 (4), 2022.
SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort studyJournal Article
Anaesthesia, 77 (1), 2022.
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort studyJournal Article
Anaesthesia, 76 (11), 2021.
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort studyJournal Article
Br J Surg, 108 (9), 2021.
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort studyJournal Article
Anaesthesia, 76 (6), 2021.
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene StudyJournal Article
Cancers (Basel), 13 (11), 2021.
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical TrialJournal Article
JAMA Oncol, 6 (3), 2020.
How Wide Should Margins Be for Phyllodes Tumors of the Breast?Journal Article
Breast J, 23 (3), 2017.
Impact of physical activity in group versus individual physical activity on fatigue in patients with breast cancer: A pilot studyJournal Article
Breast, 35 , 2017.
Envisager une mastectomie préventive avec ou sans reconstruction mammaireBook
Réseau ROSE et CHU de Québec-Université Laval, Québec, 2016.
- NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
- Vers des trajectoires de soins en cancer du sein personnalisées en fonction du risque et des besoins des patientes: une étude de faisabilité et d'acceptabilité, from 2023-04-01 to 2025-03-31
Recently finished projects
- Exploring the impact for COVID-19 pandemic on women with breast cancer in Quebec, from 2021-12-01 to 2023-09-30
- Tomosynthesis Mammographic Imaging Screening Trial (TMIST), from 2017-09-11 to 2022-12-25